SGLT2 inhibitors are new glucose-lowering agents for type 2 diabetes. They promote glucose loss into urine, which lowers blood glucose levels. However, little is known regarding the changes to kidney physiology when this system is manipulated with these drugs. There is evidence that SGLT2 inhibitors do not protect against kidney disease in diabetic mice, despite being an effective blood glucose-lowering agent. I aim to characterise the changes to kidney function upon SGLT2 blockade in diabetes.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100191
Funder
Australian Research Council
Funding Amount
$250,000.00
Summary
An advanced mass spectrometer for applications in phospho-proteomics, glycomics and top-down sequencing of proteins. This cutting-edge mass spectrometry facility will benefit the Hunter Valley research community comprising 100 researchers in this field. It will enable the researchers to enhance their research productivity in areas of national importance, including better understanding the etiology of disease states, reproductive health and the regulation of plant growth.